Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doranidazole

Drug Profile

Doranidazole

Alternative Names: PR 350; RP 343

Latest Information Update: 21 Aug 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyoto University; POLA PHARMA
  • Developer POLA PHARMA; Shuttle Pharmaceuticals
  • Class Imidazoles; Radiosensitisers
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Research Pancreatic cancer

Most Recent Events

  • 21 Aug 2017 Doranidazole is still in phase IIa trial for Non-small cell lung cancer in Japan
  • 15 Aug 2017 Doranidazole licensed to Shuttle Pharma in USA
  • 15 Aug 2017 Dranidazole licensed to Shenzhen Main Luck Pharmaceuticals in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top